G100192 can be an orally-available small molecule therapeutic, which includes demonstrated successful Proof Concept in pre-clinical studies for cachexia . Related StoriesNeurological examining accessibility and affordability: an interview with Dr Joseph HigginsCharley’s Fund and the Nash Avery Base will support the expenses of pre-clinical studies to assess the potential effectiveness of G100192 in dealing with Duchenne muscular dystrophy. While investigating this new indication, Galapagos shall continue steadily to develop the SARM therapeutic for cachexia, and programs to initiate a Phase I clinical trial in healthy volunteers initially of 2010.A standardized molecular monitoring BCR-ABL test with greater reproducibility is expected to support optimal individual management decisions. By shifting to a rigorously developed, regulatory-cleared/approved test which can be from the IS, the collaboration aims to reduce the variability that is presently inherent in BCR-ABL examining. Related StoriesSingle gene variation may influence obesity in children, adultsScalable creation of gene therapy vectors: an interview with Frank UbagsApoE4-carrying males with Alzheimer's disease vulnerable to brain bleeds Over the healthcare market, focused diagnostic tests offer a very real opportunity for improved individual care and resource administration through more directed treatment decisions, said John Bishop, Cepheid’s Chief Executive Officer.